Dr. Paul Stoffels
Dr. Paul Stoffels
Share
Global Public Health
Why now is the time to tackle DR-TB
Why now is the time to tackle DR-TB
Share

Drug-resistant TB (DR-TB) is on the rise with 558,000 new cases a year. It is the only airborne drug-resistant epidemic and responsible for nearly 1/3 of all deaths from antimicrobial resistance (AMR) globally.

A new report by The Economist Intelligence Unit (EIU), and made possible with support from Johnson & Johnson, emphasizes the urgent need for global action to address the growing threat of DR-TB.

Learn more.

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue